EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares [Yahoo! Finance]
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Warning! GuruFocus has detected 4 Warning Signs with EYPT. EyePoint Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapeutics for eye diseases. The company's pipeline includes treatments for conditions such as uveitis, diabetic macular edema, and other eye disorders. Over the past year, the insider has sold a total of 71,382 shares and has not made any purchases of the company's stock. The insider transaction history for EyePoint Pharmaceuticals Inc shows a pattern of insider activity. In the past year, there have been 3 insider buys and 19 insider sells. On the day of the insider's recent sell, shares of EyePoint Pharmaceuticals Inc were trading at $25.01, giving the company a market cap of $1.216 billion. The stock's price-to-GF-Value ratio stands at 4.25, with a GuruFocus Value of $5.88, indicating that EyePoint Pharmaceuticals Inc is significantly overvalued based on its GF Value. The GF Value is calculated considering h
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists [Yahoo! Finance]Yahoo! Finance
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina SpecialistsGlobeNewswire
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22% [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 3/7/24 - Beat
EYPT
Sec Filings
- 4/26/24 - Form DEF
- 4/26/24 - Form DEFA14A
- 4/22/24 - Form 3
- EYPT's page on the SEC website